Barbara Weber, M.D., is a distinguished leader in the field of oncology and serves as the President, Chief Executive Officer, and Director at Tango Therapeutics Inc. Dr. Weber's professional journey is marked by her significant contributions to cancer research and drug development. She earned her medical degree from the University of Pennsylvania and completed her residency and fellowship in medical oncology at the Johns Hopkins Hospital. Her career trajectory includes pivotal roles at leading pharmaceutical companies, where she has driven the development of innovative cancer therapies. Before joining Tango Therapeutics, Dr. Weber held key positions at companies such as Novartis and GSK, where she spearheaded oncology drug development programs that advanced the treatment landscape for various cancers. Her tenure at these organizations was characterized by her ability to translate scientific discoveries into effective therapeutic solutions, earning her a reputation as a visionary in the field. At Tango Therapeutics, Dr. Weber leads the company's mission to discover and develop precision cancer medicines that target synthetic lethal interactions within cancer cells. Her strategic vision and leadership are instrumental in guiding Tango Therapeutics towards its goal of transforming cancer treatment through targeted therapies. Under Dr. Weber's leadership, Tango Therapeutics has made significant strides in advancing its pipeline of novel cancer treatments. Her role extends beyond executive management; she actively engages with the scientific community to foster collaboration and innovation. Dr. Weber's commitment to improving patient outcomes is evident in her dedication to the company's mission and her efforts to bring groundbreaking therapies to market. Her expertise and leadership continue to drive Tango Therapeutics forward as a pioneer in the field of precision oncology.